智药元创
Intelligent Medicine Original
What Science Can Do
Protein Drug Design
A multidimensional, quick-response database for design validation, providing a rapid new method verification platform for pharmaceutical companies, and accelerating screening.
User-specified workflows, graphical user interface, one-click generation design platform
Utilizing artificial intelligence technology, efficiently design based on the structural and functional characteristics of specific disease targets
Choose Us
Team
Founded by top experts and teams from Shanghai Jiao Tong University in drug design and clinical research
Innovation
Developed a high-throughput protein drug design method based on generative artificial intelligence large language models, increasing diversity by 15% and running 2.2 times faster compared to the most commonly used methods.
Collaboration
Collaborating with WuXi Biologics, Nutshell Therapeutics, BeiGene, Pi Health, Ruijin Hospital, Renji Hospital, West China Hospital, Beijing University of Chinese Medicine, and others
Pipeline
Focusing on peptide drug screening, conducting experimental validations of protein solubility, affinity, and activity, aiming to solve major diseases such as endocrine disorders, gastrointestinal diseases, and bone disorders
About Us
IMO is a medical technology company founded by researchers from Shanghai Jiao Tong University. Founded in November 2023, the company has already built a comprehensive, graphical, and one-click platform for computational screening targeting artificial intelligence protein drug design. It has collaborated with multiple listed pharmaceutical companies both domestically and internationally to accelerate protein drug development and develop its own protein drug pipelines. Additionally, it has partnered with several top-tier hospitals to develop AI-based diagnostic and predictive tools.
The mission of IMO is to use generative artificial intelligence technology to develop innovative drug screening algorithms, and is committed to solving the problems of long protein drug screening time and low success rate. Our goal is to develop efficient and accurate protein drug screening software, focusing on peptide drug screening, and conducting experimental verification of protein solubility, affinity, and activity, in order to solve major disease problems such as endocrine, digestive tract, and bone lesions. We believe that through the power of artificial intelligence, we can open a new chapter in the research and development of drugs and diagnosis and treatment, bringing greater hope and possibility to the health of all mankind.